Abstract
For the past ten years or so, proton pump inhibitors (PPI) such as omeprazole, lansoprazole, or pantoprazole, have become the reference treatment for peptic disorders in adults. PPIs have recently begun to be used in pediatrics, and this use is likely to expand. They act on the final step of gastric acid secretion by completely inhibiting the ATPase (proton pump) at the surface of the gastric parietal cells, thus yielding long term inhibition which is not correlated with the plasma concentration of the drug, in contrast to the effects of H2-blocker drugs. Our knowledge of this new class of treatment in pediatrics is still fragmentary, but the reported pharmacokinetic and clinical data indicate that they are suitable for use in children. While the short-term risk of complications appears to be minimal, the tolerance of these drugs in chronic use requires careful monitoring because of the potential consequences of prolonged inhibition of acid secretion.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
